PMC:6562565 / 66153-67039 JSONTXT

{"project":"MyTest","denotations":[{"id":"31244820-30649750-35366399","span":{"begin":629,"end":632},"obj":"30649750"},{"id":"31244820-29045511-35366400","span":{"begin":871,"end":874},"obj":"29045511"},{"id":"31244820-28187291-35366401","span":{"begin":876,"end":879},"obj":"28187291"},{"id":"31244820-28421069-35366402","span":{"begin":881,"end":884},"obj":"28421069"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"There are two main approaches to ACT. Either autologous tumor-reactive T cells are expanded from tumor biopsies prior to patient re-infusion [i.e., tumor infiltrating lymphocyte (TIL) therapy], or peripheral blood T cells are gene-engineered to express a tumor-specific T cell receptor (TCR), or a so-called chimeric antigen receptor (CAR; a fusion protein that links scFv-mediated tumor antigen-binding with intracellular endo-domains associated with T cell activation). Cancer patients are typically lymphodepleted prior to ACT, and following infusion they receive high doses of IL-2, both of which support T cell engraftment (426). TIL therapy has achieved robust and durable responses in advanced melanoma patients, while CAR therapy targeting CD19 has yielded unprecedented clinical responses against a variety of advanced, treatment-refractory B cell malignancies (118, 427, 428)."}

{"project":"TEST0","denotations":[{"id":"31244820-157-164-3850547","span":{"begin":629,"end":632},"obj":"[\"30649750\"]"},{"id":"31244820-236-243-3850548","span":{"begin":871,"end":874},"obj":"[\"29045511\"]"},{"id":"31244820-229-236-3850549","span":{"begin":876,"end":879},"obj":"[\"28187291\"]"},{"id":"31244820-234-241-3850550","span":{"begin":881,"end":884},"obj":"[\"28421069\"]"}],"text":"There are two main approaches to ACT. Either autologous tumor-reactive T cells are expanded from tumor biopsies prior to patient re-infusion [i.e., tumor infiltrating lymphocyte (TIL) therapy], or peripheral blood T cells are gene-engineered to express a tumor-specific T cell receptor (TCR), or a so-called chimeric antigen receptor (CAR; a fusion protein that links scFv-mediated tumor antigen-binding with intracellular endo-domains associated with T cell activation). Cancer patients are typically lymphodepleted prior to ACT, and following infusion they receive high doses of IL-2, both of which support T cell engraftment (426). TIL therapy has achieved robust and durable responses in advanced melanoma patients, while CAR therapy targeting CD19 has yielded unprecedented clinical responses against a variety of advanced, treatment-refractory B cell malignancies (118, 427, 428)."}

{"project":"2_test","denotations":[{"id":"31244820-30649750-35366399","span":{"begin":629,"end":632},"obj":"30649750"},{"id":"31244820-29045511-35366400","span":{"begin":871,"end":874},"obj":"29045511"},{"id":"31244820-28187291-35366401","span":{"begin":876,"end":879},"obj":"28187291"},{"id":"31244820-28421069-35366402","span":{"begin":881,"end":884},"obj":"28421069"}],"text":"There are two main approaches to ACT. Either autologous tumor-reactive T cells are expanded from tumor biopsies prior to patient re-infusion [i.e., tumor infiltrating lymphocyte (TIL) therapy], or peripheral blood T cells are gene-engineered to express a tumor-specific T cell receptor (TCR), or a so-called chimeric antigen receptor (CAR; a fusion protein that links scFv-mediated tumor antigen-binding with intracellular endo-domains associated with T cell activation). Cancer patients are typically lymphodepleted prior to ACT, and following infusion they receive high doses of IL-2, both of which support T cell engraftment (426). TIL therapy has achieved robust and durable responses in advanced melanoma patients, while CAR therapy targeting CD19 has yielded unprecedented clinical responses against a variety of advanced, treatment-refractory B cell malignancies (118, 427, 428)."}